Novo Nordisk in China

As the leader in the Chinese diabetes market, Novo Nordisk has always been committed to changing diabetes. Since its establishment in 1994, the Novo Nordisk (China) Pharmaceuticals Co., Ltd. has been prominently growing its presence in the country. Headquartered in Beijing, Novo Nordisk China has established a distribution network throughout the country, providing services to patients across mainland China as well as Hong Kong, Macau and Taiwan. As of end-2017, Novo Nordisk had 4,329 employees in China. Novo Nordisk was the first biopharmaceutical company to establish a Research center in China. Located in Beijing, the research center is an integral part of Novo Nordisk’s global R&D system, mandated to develop new products and production technologies in collaboration with the company headquarters. Novo Nordisk Tianjin Plant is a strategic overseas production base of Novo Nordisk. Thanks to massive capital investment and a technological expertise, Novo Nordisk Tianjin Plant is now capable of supplying diabetes treatment products to both the Chinese and the global markets. The unrelenting development of Novo Nordisk in China directly reflects the Company’s long-term commitment to the Chinese market.